{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:30:51Z","timestamp":1761921051484,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SCHE 2092\/3-1, SCHE 2092\/4-1 [RP9, CP2, CP3] and CRU329, Project-ID 43198400\u2013SFB1453"],"award-info":[{"award-number":["SCHE 2092\/3-1, SCHE 2092\/4-1 [RP9, CP2, CP3] and CRU329, Project-ID 43198400\u2013SFB1453"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMBF"},{"name":"Universit\u00e4ts-Herzzentrum Freiburg - Bad Krozingen GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backround<\/jats:title>\n                <jats:p>Accurate surrogate parameters for radio resistance are warranted for individualized radiotherapy (RT) concepts in prostate cancer (PCa). The purpose of this study was to assess intertumoral heterogeneity in terms of radio resistance using an ex-vivo \u03b3H2AX assay after irradiation of prostate biopsy cores and to investigate its correlation with clinical features of respective patients as well as imaging and genomic features of tumor areas.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty one patients with histologically-proven PCa and pre-therapeutic multiparametric resonance imaging and prostate-specific membrane antigen positron emission tomography were included in the study. Biopsy cores were collected from 26 PCa foci. Residual \u03b3H2AX foci were counted 24\u00a0h after ex-vivo irradiation (with 0 and 4\u00a0Gy) of biopsy specimen and served as a surrogate for radio resistance. Clinical, genomic (next generation sequencing) and imaging features were collected and their association with the radio resistance was studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total 18 PCa lesions from 16 patients were included in the final analysis. The median \u03b3H2AX foci value per PCa lesion was 3.12. According to this, the patients were divided into two groups (radio sensitive vs. radio resistant) with significant differences in foci number (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The patients in the radio sensitive group had significantly higher prostate specific antigen serum concentration (<jats:italic>p<\/jats:italic>\u2009=\u20090.015), tumor areas in the radio sensitive group had higher SUV (standardized uptake values in PSMA PET)-max and -mean values (<jats:italic>p<\/jats:italic>\u2009=\u20090.0037, <jats:italic>p<\/jats:italic>\u2009=\u20090.028) and lower ADC (apparent diffusion coefficient-mean values, <jats:italic>p<\/jats:italic>\u2009=\u20090.049). All later parameters had significant (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) correlations in Pearson\u2019s test. One patient in the radio sensitive group displayed a previously not reported loss of function frameshift mutation in the <jats:italic>NBN<\/jats:italic> gene (c.654_658delAAAAC) that introduces a premature termination codon and results in a truncated protein.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this pilot study, significant differences in intertumoral radio resistance were observed and clinical as well as imaging parameters may be applied for their prediction. After further prospective validation in larger patient cohorts these finding may lead to individual RT dose prescription for PCa patients in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02131-1","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T07:02:51Z","timestamp":1664953371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ex vivo \u03b3H2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters"],"prefix":"10.1186","volume":"17","author":[{"given":"Ioana M.","family":"Marinescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rogg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"von B\u00fcren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Kamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cordula A.","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Fountzila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriaki","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa","family":"Bettermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juri","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Benndorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Adebahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca L.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"issue":"1","key":"2131_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2131_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220\u201341.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2131_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.juro.2006.06.002","volume":"176","author":"MJ Zelefsky","year":"2006","unstructured":"Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176(4):1415\u20139.","journal-title":"J Urol"},{"issue":"7","key":"2131_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39(7):787\u201396.","journal-title":"J Clin Oncol"},{"issue":"10323","key":"2131_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360.","journal-title":"Lancet"},{"issue":"11","key":"2131_CR6","first-page":"6","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):6.","journal-title":"JAMA"},{"issue":"3","key":"2131_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.radonc.2017.08.020","volume":"124","author":"C De-Colle","year":"2017","unstructured":"De-Colle C, Yaromina A, Hennenlotter J, Thames H, Mueller AC, Neumann T, et al. Ex vivo \u03b3H2AX radiation sensitivity assay in prostate cancer: inter-patient and intra-patient heterogeneity. Radiother Oncol. 2017;124(3):386\u201394.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2131_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1615\/CritRevOncog.2018025946","volume":"23","author":"L Chaiswing","year":"2018","unstructured":"Chaiswing L, Weiss HL, Jayswal RD, Clair DKST, Kyprianou N. Profiles of radioresistance mechanisms in prostate cancer. Crit Rev Oncog. 2018;23(1):39\u201367.","journal-title":"Crit Rev Oncog"},{"key":"2131_CR9","doi-asserted-by":"crossref","unstructured":"Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. \u03b3H2AX and cancer. Nat Rev Cancer. 2008;8(12):957-67.","DOI":"10.1038\/nrc2523"},{"issue":"1","key":"2131_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.radonc.2011.07.001","volume":"100","author":"A Menegakis","year":"2011","unstructured":"Menegakis A, Eicheler W, Yaromina A, Thames HD, Krause M, Baumann M. Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. Radiother Oncol. 2011;100(1):137\u201344.","journal-title":"Radiother Oncol"},{"issue":"3","key":"2131_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.radonc.2015.03.026","volume":"116","author":"A Menegakis","year":"2015","unstructured":"Menegakis A, von Neubeck C, Yaromina A, Thames H, Hering S, Hennenlotter J, et al. \u03b3H2AX assay in ex vivo irradiated tumour specimens: a novel method to determine tumour radiation sensitivity in patient-derived material. Radiother Oncol. 2015;116(3):473\u20139.","journal-title":"Radiother Oncol"},{"key":"2131_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","volume":"141","author":"AS Bettermann","year":"2019","unstructured":"Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, et al. [68Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard\u2013implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol. 2019;141:214\u20139.","journal-title":"Radiother Oncol"},{"key":"2131_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.600690","volume":"10","author":"SKB Spohn","year":"2020","unstructured":"Spohn SKB, Kramer M, Kiefer S, Bronsert P, Sigle A, Schultze-Seemann W, et al. Comparison of manual and semi-automatic [18F]PSMA-1007 PET based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference. Front Oncol. 2020;10: 600690.","journal-title":"Front Oncol"},{"key":"2131_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5114\/jcb.2016.61067","volume":"3","author":"C Zamboglou","year":"2016","unstructured":"Zamboglou C, Rischke HC, Meyer PT, Knobe S, Volgeova-Neher N, Kollefrath M, et al. Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. J Contemp Brachyther. 2016;3:241\u20138.","journal-title":"J Contemp Brachyther"},{"issue":"16","key":"2131_CR15","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.7150\/thno.61207","volume":"11","author":"SKB Spohn","year":"2021","unstructured":"Spohn SKB, Bettermann AS, Bamberg F, Benndorf M, Mix M, Nicolay NH, et al. Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. Theranostics. 2021;11(16):8027\u201342.","journal-title":"Theranostics"},{"key":"2131_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2384894","volume":"2016","author":"M Kroenig","year":"2016","unstructured":"Kroenig M, Schaal K, Benndorf M, Soschynski M, Lenz P, Krauss T, et al. Diagnostic accuracy of robot-guided, software based transperineal MRI\/TRUS fusion biopsy of the prostate in a high risk population of previously biopsy negative men. BioMed Res Int. 2016;2016:1\u20136.","journal-title":"BioMed Res Int"},{"issue":"2","key":"2131_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/15384047.2018.1523849","volume":"20","author":"S Ikeda","year":"2019","unstructured":"Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2019;20(2):219\u201326.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"2131_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","volume":"16","author":"SY Ku","year":"2019","unstructured":"Ku SY, Gleave ME, Beltran H. Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019;16(11):645\u201354.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"2131_CR19","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1158\/1535-7163.MCT-19-0531","volume":"19","author":"NA Dawson","year":"2020","unstructured":"Dawson NA, Zibelman M, Lindsay T, Feldman RA, Saul M, Gatalica Z, et al. An emerging landscape for canonical and actionable molecular alterations in primary and metastatic prostate cancer. Mol Cancer Ther. 2020;19(6):1373\u201382.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2131_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11912-019-0790-6","volume":"21","author":"A Athie","year":"2019","unstructured":"Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, et al. Targeting DNA repair defects for precision medicine in prostate cancer. Curr Oncol Rep. 2019;21(5):42.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"2131_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/bjc.2012.486","volume":"108","author":"C Cybulski","year":"2013","unstructured":"Cybulski C, Woko\u0142orczyk D, Klu\u017aniak W, Jakubowska A, G\u00f3rski B, Gronwald J, et al. An inherited NBN mutation is associated with poor prognosis prostate cancer. Br J Cancer. 2013;108(2):461\u20138.","journal-title":"Br J Cancer"},{"issue":"5","key":"2131_CR22","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s13277-013-0830-z","volume":"34","author":"G Zhang","year":"2013","unstructured":"Zhang G, Zeng Y, Liu Z, Wei W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34(5):2753\u20137.","journal-title":"Tumour Biol J Int Soc Oncodev Biol Med"},{"issue":"17","key":"2131_CR23","doi-asserted-by":"publisher","first-page":"7110","DOI":"10.1158\/0008-5472.CAN-07-6507","volume":"68","author":"Y Niu","year":"2008","unstructured":"Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, et al. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res. 2008;68(17):7110\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"2131_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1474-9726.2009.00488.x","volume":"8","author":"D Soler","year":"2009","unstructured":"Soler D, Pampalona J, Tusell L, Genesc\u00e0 A. Radiation sensitivity increases with proliferation-associated telomere dysfunction in nontransformed human epithelial cells. Aging Cell. 2009;8(4):414\u201325.","journal-title":"Aging Cell"},{"key":"2131_CR25","doi-asserted-by":"crossref","unstructured":"Moradi F, Duan H, Song H, Davidzon GA, Chung BI, Thong AEC, et al. 68Ga-PSMA-11 PET\/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment. J Nucl Med [Internet]. 2022 May 1 [cited 2022 Jun 5]; Available from: https:\/\/jnm.snmjournals.org\/content\/early\/2022\/05\/05\/jnumed.122.263897","DOI":"10.2967\/jnumed.122.263897"},{"issue":"7","key":"2131_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","volume":"59","author":"DS O\u2019Keefe","year":"2018","unstructured":"O\u2019Keefe DS, Bacich DJ, Huang SS, Heston WDW. A Perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med. 2018;59(7):1007\u201313.","journal-title":"J Nucl Med"},{"key":"2131_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","volume":"79","author":"MR Lieber","year":"2010","unstructured":"Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end joining pathway. Annu Rev Biochem. 2010;79:181\u2013211.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"2131_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.20171052","volume":"215","author":"C Kaittanis","year":"2017","unstructured":"Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2017;215(1):159\u201375.","journal-title":"J Exp Med"},{"issue":"14","key":"2131_CR29","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1128\/MCB.00084-06","volume":"26","author":"RE Conway","year":"2006","unstructured":"Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26(14):5310\u201324.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2131_CR30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1158\/0008-5472.CAN-03-2502","volume":"64","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, G\u00f3rski B, Debniak T, Gliniewicz B, Mierzejewski M, Masoj\u0107 B, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res. 2004;64(4):1215\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"2131_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/345310","volume":"72","author":"SM Edwards","year":"2003","unstructured":"Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72(1):1\u201312.","journal-title":"Am J Hum Genet"},{"issue":"10","key":"2131_CR32","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/bjc.2012.146","volume":"106","author":"D Leongamornlert","year":"2012","unstructured":"Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106(10):1697\u2013701.","journal-title":"Br J Cancer"},{"issue":"5","key":"2131_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443\u201353.","journal-title":"N Engl J Med"},{"issue":"14","key":"2131_CR34","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(14):1748\u201357.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2131_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.05.013","volume":"514","author":"YY Wang","year":"2021","unstructured":"Wang YY, Hung AC, Lo S, Hsieh YC, Yuan SSF. MRE11 as a molecular signature and therapeutic target for cancer treatment with radiotherapy. Cancer Lett. 2021;514:1\u201311.","journal-title":"Cancer Lett"},{"issue":"22","key":"2131_CR36","doi-asserted-by":"publisher","first-page":"11081","DOI":"10.18632\/oncotarget.2404","volume":"5","author":"A Berlin","year":"2014","unstructured":"Berlin A, Lalonde E, Sykes J, Zafarana G, Chu KC, Ramnarine VR, et al. NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget. 2014;5(22):11081\u201390.","journal-title":"Oncotarget"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02131-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02131-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02131-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T07:03:37Z","timestamp":1664953417000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02131-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2131"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02131-1","relation":{},"ISSN":["1748-717X"],"issn-type":[{"type":"electronic","value":"1748-717X"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Medical Faculty of the University of\u00a0Freiburg (Nr 274-18_v5). All patients signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}